Can a single shot keep tetanus at bay?

NCT ID NCT06120751

Completed Prevention Sponsor: CanSino Biologics Inc. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial is testing whether a single dose of an experimental tetanus vaccine is safe and triggers a protective immune response in adults aged 18 and older. Participants will receive either the new vaccine or a control vaccine, and researchers will measure antibody levels and monitor for side effects. The goal is to see if this vaccine could be a reliable way to prevent tetanus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental adsorbed tetanus vaccine (TTVA)
What this could lead to: If successful, this could provide a safe and effective option for protecting adults against tetanus, a serious bacterial infection.
What could go wrong: As with any vaccine, there is a risk of side effects, and the immune response may not be strong enough. This is a single trial, and results need confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETANUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TETANUS

Contacts and locations

Locations

Center for Disease Control and Prevention, Qixingguan District, Bijie City

Bijie, Guizhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.